| Intracranial efficacy of selpercatinib in RET fusion-positive non–small cell lung cancers on the LIBRETTO-001 trial V Subbiah, JF Gainor, GR Oxnard, DSW Tan, DH Owen, BC Cho, ... Clinical Cancer Research 27 (15), 4160-4167, 2021 | 78 | 2021 |
| Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study KA Autio, CA Klebanoff, D Schaer, JSW Kauh, SF Slovin, M Adamow, ... Clinical Cancer Research 26 (21), 5609-5620, 2020 | 40 | 2020 |
| On estimation of the optimal treatment regime with the additive hazards model S Kang, W Lu, J Zhang Statistica Sinica 28 (3), 1539, 2018 | 18 | 2018 |
| Subgroup detection and sample size calculation with proportional hazards regression for survival data S Kang, W Lu, R Song Statistics in medicine 36 (29), 4646-4659, 2017 | 17 | 2017 |
| Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma MG Zauderer, EW Alley, J Bendell, E Capelletto, TM Bauer, S Callies, ... Investigational New Drugs 39, 1081-1088, 2021 | 16 | 2021 |
| Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant … KA Autio, CA Klebanoff, D Schaer, JS Kauh, SF Slovin, VS Blinder, ... Journal of Clinical Oncology 37 (15_suppl), 2548-2548, 2019 | 16 | 2019 |
| Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on … C Sweeney, IJ Percent, S Babu, J Cultrera, BA Mehlhaff, OB Goodman, ... Journal of Clinical Oncology 37 (15_suppl), 5009-5009, 2019 | 12 | 2019 |
| What’s in a side effect? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension PJ Leary, S Kang, TM Kolb, BA Maron, DD Ralph, Y Rao, RJ Tedford, ... International Journal of Cardiology 240, 386-391, 2017 | 11 | 2017 |
| Efficient estimation for accelerated failure time model under case‐cohort and nested case‐control sampling S Kang, W Lu, M Liu Biometrics 73 (1), 114-123, 2017 | 7 | 2017 |
| Abstract CT020: Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma MG Zauderer, DM Hyman, EW Alley, JC Bendell, S Novello, TM Bauer, ... Cancer Research 78 (13_Supplement), CT020-CT020, 2018 | | 2018 |
| Flexible Estimation and Testing Methods for Survival Data with Application in Epidemiology and Precision Medicine S Kang North Carolina State University, 2017 | | 2017 |
| Statistica Sinica Preprint No: SS-2016-0543R1 S Kang, J Zhang | | |
